Patent intelligence · US
US 9850244
Method for preparing Palbociclib
Method for preparing Palbociclib
Patent details — US 9850244
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 26, 2017
- Expiration
- Dec 21, 2037
- Applicant
- Suzhou Miracpharma Technology Co., Ltd.
- Claims
- 10
- CPC classes
- A61K, A61K31/535, A61K31/5395
Quick answer
US 9850244 (Method for preparing Palbociclib) is held by Suzhou Miracpharma Technology Co., Ltd.. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Suzhou Miracpharma Technology Co., Ltd.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/535, A61K31/5395
More from Suzhou Miracpharma Technology Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Related coverage
Frequently asked questions
What is US patent 9850244?
US 9850244 (Method for preparing Palbociclib) is held by Suzhou Miracpharma Technology Co., Ltd.. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9850244?
Suzhou Miracpharma Technology Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9850244 expire?
Our index shows an expiration date of Dec 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.